Mindera Health™ Announces Coverage with Evidence Project with Highmark, Inc. to Advance Moderate-to-Severe Psoriasis Patient Care and Reduce Specialty Drug Spending
Project will evaluate Mind.Px’s™ impact on physician “trial and error” prescribing behavior and overall net savings by prescribing the correct biologic class the first time
SAN DIEGO, CA – April 11, 2023 – Mindera Health™, the developer of Mind.Px, the first realization of precision medicine in psoriasis, has initiated a coverage with evidence project with Highmark Inc. and its health plan affiliates for Pennsylvania, West Virginia and Delaware. The program will evaluate trends in physician utilization, patient outcomes, drug switching, and overall net savings versus a control group.
In the United States, psoriasis affects more than three percent[i] of the population, leading to healthcare…